ChromaDex (CDXC) | Stock Overview & Key Data
ChromaDex Performance Comparison
Stock Range
Today's Range
Low: $9.41
High: $9.81
on September 26, 2025
52 Week Range
Low: $3.18
High: $14.69
on October 10, 2024
All-Time High: $23.66 on February 22, 2021
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$754.7M
EPS
N/A
P/E Ratio (TTM)
71.55
Forward P/E
65.58
P/B Ratio
13.72
PEG Ratio
-0.09
Div. Yield
N/A
ROE
18.55%
Beta
N/A
Debt to Equity
0.06
Financial Highlights
Profitability
Gross Margin
63.42%
Operating Margin
7.76%
Profit Margin
61.84%
Returns and Earnings
Return on Assets (TTM)
12.52%
Return on Equity (TTM)
18.55%
EBITDA
$14.7M
Net Income (TTM)
$8.6M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$1.29
Quarterly Revenue Growth (YoY)
4.66%
Quarterly Earnings Growth (YoY)
37.59%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| ChromaDex CDXC | 754.74M Small-cap | -1.01% | -2.79% | -29.38% | 27.58% | 78.10% | 156.84% | 693.50% | 148.35% |
| Vertex VRTX | 100.41B Large-cap | 7.07% | 1.96% | -10.54% | -15.44% | 0.76% | -10.20% | 38.49% | 51.45% |
| Alnylam ALNY | 60.38B Large-cap | 2.54% | 3.13% | 39.79% | 72.77% | 97.32% | 72.02% | 135.43% | 213.60% |
| Celcuity CELC | 1.97B Small-cap | -4.85% | -7.76% | 278.99% | 427.99% | 276.39% | 228.59% | 392.23% | 755.02% |
| Vera Therapeutics VERA | 1.91B Small-cap | 8.27% | 29.10% | 23.42% | 23.74% | -30.83% | -28.53% | 46.24% | 153.83% |
| Liquidia LQDA | 1.90B Small-cap | -2.45% | -23.37% | 81.59% | 50.83% | 80.99% | 96.41% | 302.57% | 307.06% |
Ownership & Short Interest
Insider Ownership
N/A
Institutional Ownership
N/A
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
858K
Average 90-Day Volume
848K
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is CDXC's 52-week high and low?
- In the last 52 weeks, ChromaDex reached a high of $14.69 (on N/A) and a low of $3.18 (on October 10, 2024).
- What is the market cap and P/E ratio for CDXC?
- Curious about ChromaDex's size and valuation? Its market capitalization stands at 754.74M. When it comes to valuation, the P/E ratio (trailing twelve months) is 71.55, and the forward P/E (looking ahead) is 65.58.
- Does CDXC pay dividends? If so, what's the yield?
- As for dividends, ChromaDex isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are ChromaDex's main competitors or similar companies to consider before investing?
When looking at ChromaDex, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX100.41B Healthcare Biotechnology -10.20% 38.49% Alnylam
ALNY60.38B Healthcare Biotechnology 72.02% 135.43% Celcuity
CELC1.97B Healthcare Biotechnology 228.59% 392.23% Vera Therapeutics
VERA1.91B Healthcare Biotechnology -28.53% 46.24% Liquidia
LQDA1.90B Healthcare Biotechnology 96.41% 302.57% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for ChromaDex Corp.? (e.g., ROE, Debt/Equity)
- To get a sense of ChromaDex's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 18.55%, the Debt to Equity ratio from the most recent quarter is 0.06, and its Gross Profit Margin stands at 63.42%.
- What is the recent revenue and earnings growth for CDXC?
- Looking at ChromaDex's growth, its revenue over the trailing twelve months (TTM) was $100M. Compared to the same quarter last year (YoY), quarterly revenue grew by 4.66%, and quarterly earnings saw a YoY growth of 37.59%.
- How much of CDXC stock is held by insiders and institutions?
- Wondering who owns ChromaDex stock? Company insiders (like executives and directors) hold about N/A of the shares, while institutional investors (such as mutual funds and pension funds) own approximately N/A.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.